In this study, the levels of the cysteine proteinase -cathepsin B were measured in diseased synovial fluids using a steady state fluorometric assay. Cathepsin B-like activity was shown to be present in all the samples analysed, with the rheumatoid arthritic synovial fluids possessing significantly higher concentrations (mean value ca. 416 mg/1) than the osteoarthritic fluids (mean value ca. 142.4 mg/1). In addition, upon treatment with pepsin, all of the rheumatoid arthritis samples were shown to possess additional cathepsin B-like activity, suggesting the presence of a reservoir of latent precursor molecules. By utilising a recently developed biotinylated affmity label for cathepsin B-like proteinases and sheep anti-(human cathepsin B) antibodies, used in combination with SDS-PAGE and Western blotting, the rheumatoid arthritic synovial cathepsin B was shown to exist in two forms with apparent molecular masses of M r 29 000 and 42 000. We propose that the former is a ftmctionally active proteinase, whereas the latter is a pepsin activatable proform which, when cleaved by this aspartyl proteinase, is converted into a catalytically competent species of M f 20000.
Introduction
Arthritis encompasses almost 200 different illnesses, of which osteoarthritis and rheumatoid arthritis are the mpst widespreäd. With the limited availability of biochemical markers, early diagnösis is almost impossible and referräl, to the clinic is usually the result of the patient experiencing paiü, stiffiiess and loss of joint function. In a large majority of patients, the disease has progressed to such a degree, that the önly remaining remedial action of total joint replacement. In the majority of the main classes of arthritic disease such äs osteoarthritis and rheumatoid arthritis, there is massive degradation of the articular cärtilage -the cushion in the synovial joint -causing the increase in pain and loss of joint function (!)·. Much attention has been di- ' ) Funding Organisati ons The Department of Education for Northern Irel ! and, Rathgael House, Bailoo Roadj Bangor, Co Down BT19 7PR rected towards identifying those agents that are capable not only of bringing about such destruction of the articular surfaces, but also of the synovial fluid, the mechanical properties of which are also known to deteriorate with disease (1) . One class of agents thought to be capable of such degradation are the proteinases and, in particulär, much attention has focused on the possible involvement of the cysteine proteinases in arthritic disease (2) .
It is known, for example, that cathepsin B is secreted from rheumatoid synoviocytes into the synovial fluid and thus naay be involved in the in vivo degradation of connective tissue proteins (2) . This thesis seems all the more reasonable in light of the in vitro studies demonstrating that cathepsin B can degrade various connective tissue constituents such äs collagen and proteoglycans (3) (4) (5) . Under nonnal circumstances, any cathepsin B that is secreted/released into the synovial fluid is efficiently neutralised by proteinaceous inhibitors such äs Eur. J, Clin. Chem. Clin. Biochera, / Vol. 32,1994 / No. 6 haptoglobulin and a 2 -macroglobulin (6), three α\ and a 2 thiol protease Inhibitors (7) (8) (9) and the cystatins such s cystatin C (10) . In contrast, in diseased conditions, an imbalance is thought to exist between proteinase and inhibitor -in favour of the former, and the proteinases are free to degrade the articular cartilage and other tissues in the joint (11) . Other studies have demonstrated the possible therapeutic value of developing selective cathepsin B inhibitors based on the peptidyl fluoromethyl ketones (12, 13) .
It is against this background that we have undertaken this present study on the detection, quantification and partial characterisation of cathepsin B-like proteinases in the synovial fluid of patients suffering from osteoarthritis and rheumatoid arthritis. This has been achieved by a combination of methods including steady-state fluorimetric assays and a recently developed Western blotting technique utilising a biotinylated afFmity label for cathepsin B-like proteinases (14, 15) .
Materials and Methods

Sample collection
In order to analyse the enzymatic properties of synovial fluid, samples were collected from patients, who were undergoing joint replacement surgery at Musgrave Park Hospital Belfast, and also from patients at the Rheumatology Outpatient Clinic, Belfast City Hospital, Belfast. Diagnosis was determined according to the criteria outlined by the American Rheumatism Association (16) . All samples were obtained in undiluted form immediately prior to surgical procedures. In addition, the relevant medical Information and history was obtained, by the surgeon, in an accompanying proforma with each sample. The proforma was designed not only to assist in the diagnosis but to provide the raedical Information to explain the results in terms of the pathogenesis of the joint disease.
Synthesis of affinity labels
The diazomethane afFmity labels, N-benzyloxycarbonyl-phenylalan yl-alanine-diazomethane (Cbz-Phe-Ala-CHN 2 )
2 ) and N-benzyloxycarbonyl-phenylalanyl-tyrosine(OBut)-diazomethane (CbzPhe-Tyr-(OBut)-CHN 2 ) were prepared by the general procedures (17, 18) and had melting points in close agreement with the literature values (19) . The biotinylated affinity label N-biotinyl-phenylalanyl-alanine-diazomethane (Bio-Phe-Ala-CHN 2 ) was prepared by the cited procedure (14) .
Sample preparation
Each of the samples was centrifuged at 5000 g for 30 min in order to remove any contaminants such s blood and debris associated with the surgical Operation. The supernatant was then stored at -15 °C prior to utilisation in the enzymatic analysis.
Steady state assay .Samples of synovial fluid were assayed for cathepsin B-like activity s described by Barren & Kirschke (20) . In essence, samples 2 ) Abbreviations used Bio, biotinyl; Cbz, benzyloxycarbonyl; Mee, 4-methylcoumarin-7-yl; OBut, f-butyl ether.
(50 μΐ) were added to a solution of (l ml) N-benzyloxycarbonylargmyl-arginyl-4-methylcoumarin (Cbz-Arg-Arg-NH-Mec) (Bachern, Bubendorf, Switzerland) (50 μιηοΐ/ΐ) in 100 mmol/l sodium phosphate buffer, pH 6.4 containing l mmol/l ethylenediaminetetraacetic acid disodium salt, 10 g/I Brij 35 and 2 mmol/I cysteine, maintained at 37 °C. The rate of hydrolysis was monitored continuously by mcasuring the rate of increase in fluorescence at 455 nm (excitation wavelength 383 nm) in a Perkin-Elrner MPF 44B spectrofluorimeter. This Substrate is hydrolysed by cathepsin B but not cathepsins H or L (20) . However, since kallikrein is known to degrade this Substrate (21) , control assays were carried out in the presence of the active-site-directed inhibitor Cbz-Phe-AIa-CHN 2 , which inactivates cysteine-but not serine proteinases (22) .
Pepsin activation
As pepsin-activatable precursor forms of cathepsin B-like proteinases have been detected in such fluids s ascitic fluid from patients with ovarian cancer (23, 24) and in medium conditioned by tumour breast cancer cells in culture (15) . The activation protocol described by these workers was applied to the synovial fluid samples in order to reveal any latent cathepsin B precursors that may have been present. Synovial fluid samples were treated with pepsin (Sigma, final concentration: 20 mg/1), in 0.1 mol/1 glycine/HCl buffer pH 3.0, at 37 °C. The resulting activity was then determined by a steady state assay measuring the turnover of the fluorogenic Substrate Cbz-Arg-Arg-NH-Mec. The hydrolysis of the Substrate was blocked by Cbz-Phe-Ala-CHN 2 . Time course studies revealed that maximum cathepsin B-like activity was generated after 60 minute exposure to pepsin. In the absence of pepsin, no activation of latent enzyme was observed in any f the samples studied.
Characterisation of labelled proteinases
Labelling of proteinases
To 0.5 ml of centrifuged synovial fluid was added 0.5 ml of 100 mmol/l phosphate buffer, pH 6.4, containing 2 mmql/l cysteine, l mmol/l ethylenediaminetetraacetic acid disodium salt and 10 g/l Brij 35. Ten μΐ of Bio^Phe^Ala-CHN 2 (l mmol/l in methanol) were added to this, and the solution was then incubated for two hours at room temperature. Following this, 0.5 ml of 400 g/l trichloroacetic acid was added to precipitate out the proteinaceous material, the mixture was then centriftiged for 15 min at 5000g and the supernatant was discarded. The pellet was then dissolved in 0.5 ml ofLaemmli treated buffer and then boiled for 10 min thus terminating the feaction between the enzyme and inhibitor.
Electrophoresis
One dimensional SDS electrophoresis was performed (25) with 10% slab gels run at a constant cujrrent of 30 mA using the Mighty Small II Apparatus (Hoefer Scientific). Biotinylated molecular weight Standards (Sigma Chemicals, Poole, Dorset, UK) were employed on each geh
Western blotting
Transfer of protein from gel to nitrocellulose (pore size: 0.2 mm; Schleicher und Sch ll, Dassel, Germany) was carfied put by the cited method (26) . The protein transfer was. carried out in 25 mmol/l glycine/192 mmol/l Tris/200 g/l methanol using a Transr Biot Celt (Βίο-Rad). The running time was 18 h at 100 mA, with a constant ternperature of 4 °C.
. 50 g/l solution of bovine serum albumin (Sigma) containing l g/l merthiolate and l g/l anti-foam agent (Sigma). Streptavidin/alkaline phosphatase (Vector Laboratories), diluted 1 : 1000 in blocking solution, was incubated with the nitrocellulose blot at room temperature for 2 -4 h with agitation. The blot was then washed at least six times with 0. l mol/1 Tris/HCl, pH 9.5, containing 0. l mol/1 NaCl and 5 mraol/1 MgCl 2 before the alkaline phosphatase activity was detected by using Nitro Blue Tetrazoliura (66 ml of a 75 g/l solution in 700 g/i , -dimethyl formamide/H 2 O) and 5-bromo-4-chloro-indol-3-yl phosphate (33 ml of a 50 g/l solution in N,Ndimethyi formamide) in 10 ml of the same buffer.
Innnunobloläng
The proteinaceous precipitate from samples of synovial fluid not exposed to the biotinylated probe were subjected to electrophoresis and Western blotting äs" described for the biotinylated proteins. Antibody probing of the Western blots was then carried out (27) . Sheep anti-human cathepsin B IgG (Serotec; used at l : 200 dilution) and donkey anti-sheep IgG conjugated to alkaline phosphatase (Serotec; used at l : 1000 dilution), were used äs first and , second antibodies respectively. Alkaline phosphatase activity was , detected using Nitro Blue Tetrazolium and 5-bromo-4-chloroindol-! 3-yl phosphate.
Results and Discussion
Comparison of cathepsin B levels in rheumatoid-and osteoarthritic synovial fluids JBy measuring the rate of hydrolysis of the fluorogenic : Substrate Cbz-Arg-Arg-NH-Mec, cathepsin B-like activity was quantified in the synovial fluid of patients with various arthropathies. This activity could be completely inhibited by the general cysteine protease inhibitor iodoacetamide and, additionally, the activity was also inhibited by the broad spectrum affinity label for cysteine proteinases Cbz-Phe-Ala-CHN 2 (22) , but not by the specific cathepsin L inhibitor Cbz-Phe-Tyr(OBut)-CHN 2 (19) . The exhibited inhibitor susceptibility taken in consideration with the specificity of the Substrate (Cbz-ArgArg-N£UMec), suggests that the observed activity was indicative of a cathepsin B-like proteinäse and excludes the possibility that a ksdlikrein^like enzyme is responsible for the observed Substrate hydrolysis.
The levels of active cathepsin B (mg/1) were calculated for each sample ässäyed, by refefence to a Standard solution of human cathepsin B -titrated against E-64 (20), and were then categorised by disease group (see fig. 1 ). Cathepsin B activity was detected in all synovial fluid samples studied, regardless of the disease process. Statistical analysis of these results was carried out using a statistical analysis package, SPSS for Windows 6.0 (SPSS Inc., USA). Both rheumatoid arthritis and osteoarthritis subgroups exhibited normal Ganssian distributions with the mean concentrations of cathepsin B shown to be significantly higher in rheumatoid arthritic synovial fluids (mean value 416 ± 226 mg/1) than in osteoarthritic fluids (mean value 142 ± 80 mg/l), where (29) , also found, on average, that cathepsin B levels were higher in rheumatoid arthriticwhen compared with osteoarthritic synovial fluids and sera.
A possible explanation for these findings can be found in the observation that Cathepsin B has been detected in the synovial membrane where it is thought to originale from synoviocytes (30, 31) . The higher levels of cathepsin B in rheumatoid arthritic synovial fluid may therefore be attributed to the fact that the disease is, unlike osteoarthritis, inflammatory in nature and inflammation of the synovial membrane may cause an increase in the protease secretory Output of the synoviocytes. Additionally, inflammation of the synovium may also cause an influx of such cells äs macrophages which may also be responsible for the secretion of cathepsin B and other proteases into the synovial fluid. It is known, for example, that collagenase levels are elevated in diseased, particular inflammatory, conditions again suggesting that proteolytic degradation may play an important role in arthritic disease (32) . Cathepsin B has also been identified by other workers in rheumatoid synovial fluid (31) and also in synovial fluid with various forms of arthritis (33), using immunochemical methods.
Western blot analysis of cathepsin B using Bio-Phe-Ala-CHN 2 To more fully characterise the activity present in the diseased synovial fluid, samples that had been incubated with the biotinylated affinity label Bio-Phe-Ala-CHN 2 were subjected to SDS-PAGE on 10% slab gels, äs detailed in the Materials and Methods section. This affinity label has been demonstrated to react covalently at the active-site of bovine and human cathepsin B, thüs enabling their detection -following Western blotting, by utilising various streptavidin/enzyme labels (14, 15) . Utilising this methodology, we were able to detect two major bands of apparent M T 42000 and 29000 (flg. 2, lane 3). The lower molecular weight form migrates with the same mobility äs active lysosomal cathepsin B (20) , and is in accordance with values reported by other workers, who have also identified a specific band of M T 29000 in synovial fluid (11) .
Since thjs^ biotinylated affinity label has been demonstrated to inactive both cathepsin B and L (34), it is necessary to carry out pre-incubation experiments with specific inactivators of cathepsin L that will block the incorporation of the biotinylated probe into this proteinase thus enabling one to unambiguously identify läbelled bands äs being cathepsin B-like. When samples of rheumatoid arthritic synovial fluid were pre-treated with Cbz-Phe-Tyr(OBut)-CHN 2 (0.1 mmol/1, for 30 min at 37 °C) which is just such an inactivator (19) , no dimu> ution in the incorporation of the biotinylated probe was observed (compare lane 5 -pre-treated sample with and Biotin-Phe-Ala-CHN 2 Lane 6 synovial fluid pretreated with Cbz-Phe-Ala-CHN 2 and°B iotin-Phe-Ala-CHN 2 Lane 7 biotinylated molecular weight markers lane 3 -no pre-treatment). This further strengthens our case that the species of M T 42 000 and 29 000 are cathepsin B-like. In addition earlier studies have shown that human cathepsin B-<x 2 -macroglobulm complexes were not detectable with this biotinylated probe (unpublished fesults) therefore it is unlikely'diat the steady state assay was detecting such complexes. Moreover, we consider it likely that the species of 29 000 is the active pfoteinase which is detected in the steady state assay and the M T 42 000 form is possibly a pro-form of this proteinase.
We have previously observed a similar banding pattern for a cathepsin B-like species produced by human breast cancer cells in culture (15) and in this particular instance the high molecular weight species coüld be converted, via activation with pepsin, irito a 29 000 form capable of cleaving the fluorogenic Substrate (Cbz-ArgrArg-· NH-Mec.
In order to test whether the M r 42 000 species did actually constitute a latent -but activatable reservoir of proteolytically active cathepsin B, we treated a series of synovial fluid samples with pepsin, essentially according to the protocols described in previous work (23, 24) . Figure 3 records the levels of these latent activities. From this figure it can be appreciated that all of the rheumatoid arthritis-syriovial samples possess latent cathepsin B-like activity. When this activation Step was carried out in the absence öf pepsin, but using the same buffer system (0.1 mol/1 glycine/HCl, pH 3-0), no ad. ditional activity was generated. This would tend to exclude the possibility that the M r 42 000 band is ä cathepsin L precursor, since these species are known to be efficiently activated by mild acid treatment alone (35, 36, 37) . Additionally, the fact that this pepsin^generated activity could cleave Cbz-Arg^Arg-NH-Mec, also strengthens our assertion that the M T 42 000 protein is a precursor of cathepsin B and not of cathepsin L, since the latter is incapable of eleaving this fluorogenic Substrate (20) .
The inability of the 42 000 species to hydrolyse the fluorogenic Substrate Cbz^Arg-Arg-NH-Mec, but yet iri- No. of samples 13 16 Fig corporate the biotinylated affinity label, appeared, at first sight, to represent something of a dichotomy. However, we also have observed just such behaviour with the pepsin activatable, latent cathepsin B-like species produced by human breast cancer cells in culture (15) , and a recent report on the incorporation of an 125 I-radiolabelled epoxide derivative N-(2S,3S)-3-trans-ethoxycarbonyloxirane-2-carbonyl-Z,-tyrosine benzyl ester into the catalytically inactive prepro form of papain (38) , corroborates our observations and would suggest that the proforms of the papain superfamily of cysteine proteinases do possess some inherent chemical reactivity towards certain active-site-directed affinity labels.
Therefore, we would offer the Suggestion that rheumatoid arthritic synovial fluids not only contain active cathepsin B, but also a reservoir of a latent and activatable proform.
The molecular aspects of the pepsin-activation Step were then analysed using the Western blotting protocols described above; figure 2 records the results of some of I these studies. From this figure it can be seen that the i higher molecular mass band (M T 42000) disappears ; when the sample is treated with pepsin and then läbelled with the biotinylated inhibitor (flg. 2, lane 4). In light of our studies carried out on the human breast cancer cellassociated cathepsin B mentioned above (15), we had expected to find that this decrease in the M r 42 000 form would be accompanied by a corresponding increase in the 29 000 species; but this was not the case. Rather, it was noted that a new species was generated of M r 20000. We presume that this is the species that is responsible for the 'additional' turnover of Cbz-Arg-Arg-NH-Mec that is observed uppn pepsin treatment of the samples.
Iminunological characterisation of cathepsin B-like species
In order to further the case for the presence of a cathepsin B4ike species in synovial fluid, immunological araalysis of samples iiot exposed to the biotinylated probe was carried out. Probing of such samples with anti-(cathepsiii B) antibodies gave results ^exactly comparable to those with the biotinylated probe, thus we were again able to detect the two major bands of appar^· ent M T 42 000 and 29 000 (fig. 2, lane 2) . Immunoblotting of pepsin^activated synovial fluid samples also yielded completely syminetrical results whfen compäred to the biotinylated probe ( fig. 2, lane 1) complete with the generation of the new species M r 20000. The detection and characterisation, üsing antibodies raised against active human cathepsin B, of latent forms of the proteinase has been previously reported, malignant asoites cells in culture aire known to produce a M r 40 000 proform of the enzyme which can be converted into a M r 33 000 species by pepsin activation (24) .
The absolute symmetry between the results of the labelling with the biotinylated probe and the anti-(cathepsin B) antibodies, in combination with the lack of autocatalysis of the latent form in acidic medium alone, lends further Support to our thesis that we are detecting a latent pepsin-activatable and an active form of cathepsin B.
Conclusions
1. By inference to Substrate specificity, inhibitor susceptibility and molecular weight (M T 29 000) -a cathepsin B-like species was shown to be present in the synovial fluid of patients suffering from osteoarthritis and rheumatoid arthritis.
2. By steady state analysis significantly elevated levels of cathepsin B-like activity were found in rheumatoid arthritic synovial fluid when compäred to osteoarthritic fluid -thus suggesting a possible role for this proteinase in arthritic disease coupled with possible diagnostic potential.
3. TThe action of pepsin revealed the presence of additional cathepsin B-like activity in both osteoarthritic and rheumatoid arthritic synovial fluid by steady state analysis.
4. Western blot analysis of synovial fluid revealed the presence of a higher molecular weight band (M T 42 000) -thought to be a pepsin-activatable form of cathepsin B and possibly responsible for the additional activity observed in the pepsin steady state assay.
5. Immunoblotting of fluid samples not treated with the biotinylated probe, using anti-(cathepsin B) antibodies, yielded completely symmetrical results when compäred to the Western blots using the probe, both before and after pepsin treatment. Thus lending further support to the thesis that we have detected a latent but pepsin-activatable and an active form of cathepsin B in synovial fluid.
6. In this wofk we have demonstrated the utilisation of the recently developed biotinylated affinity label Biotinyl-Phe-Ala-Diazomethane (Bio-Phe-Ala-CHN 2 ) for the detection of an active and a pepsin-activatable form of a cathepsin B-like enzyme in diseased synovial fluid.
